Evans Blue: A Specific Inhibitor of Factor VIII-Induced Platelet Agglutination

Summary

Low concentrations of Evans Blue ( < 1 μM) inhibit the agglutination of formalin-treated platelets by bovine Factor VIII or by human Factor VIII in the presence of the antibiotic ristocetin. Evans Blue is a specific inhibitor of this reaction and acts by inhibiting the binding of Factor VIII to the platelet surface.

• References

• 1 Allain J. P, and Cooper H. A. 1974; Aggregation of platelets fixed with paraformaldehyde: a study of platelet membrane receptors. Federation Proceedings 33: 244.
• 2 Bouma B. N, Wiegerinck Y, Sixma J. J, Van Mourik J. A, and Mochtar I. A. 1972; Immunological characterization of anti-haemophilic factor A (Factor VIII) which corrects abnormal platelet retention in von Willebrand’s disease. Nature, New Biology 236: 104.
• 3 Day H. J, and Holmsen H. 1972; Laboratory tests of platelet functions. Annals of Clinical Laboratory Science 2: 63.
• 4 Forbes C. D, and Prentice C. R. M. 1973; Aggregation of human platelets by purified porcine and bovine antihaemophilic factor. Nature 241: 149.
• 5 Freedman F. B, and Johnson J. A. 1969; Equilibrium and kinetic properties of the Evans Blue-albumin system. American Journal of Physiology 216: 675.
• 6 Giger M, Baumgartner H. R, and Zbinden G. 1974; Toxicological effects of Evans Blue and Congo Red on blood platelets. Agents and Actions 4: 173.
• 7 Gregersen M, and Rawson R. A. 1959; Blood volume. Physiological Reviews 39: 307.
• 8 Hartwell J. L, and Fieser L. F. 1936; Coupling of 0-tolidin.e and Chicago acid. Organic Synthesis 16: 12.
• 9 Holmsen FL, Setkowsky C. A, and Day H. J. 1974; Effects of antimycin and 2-deoxyglucose on adenine nucleotides in human platelets. Biochemical Journal 144: 385.
• 10 Howard M. A, Sawers B. J, and Firkin Gr. B. 1973; Ristocetin: A means of differentiating von Willebrand’s disease into two groups. Blood 41: 687.
• 11 Kirby E. P, and Mills D. C. B. 1975; The interaction of bovine Factor VIII with human platelets. Journal of Clinical Investigation 56: 491.
• 12 Legaz M. E, Schmer G, Counts R. B, and Davie E. W. 1973; Isolation and characterization of human Factor VIII (antihemophilic factor). Journal of Biological Chemistry 248: 2946.
• 13 Lowry O. H, Rosebrough N. J, Farr A. L, and Randall R. J. 1951; Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 193: 265.
• 14 Molnar J, and Lorano L. 1961; Studies on apyrase. Archives of Biochemistry and Biophysics 93: 353.
• 15 Mustard J. F, Perry D. W, Ardlie N. G, and Packham M. A. 1972; Preparation of suspensions of washed platelets from humans. British Journal of Haematology 22: 193.
• 16 Nishlzawa E. E, Wynalda D. J, and Lednicer D. 1974; Non-thrombogenic surface with Evans Blue. Thrombosis et Diathesis Haemorrhagica suppl. 60: 135.
• 17 Parker B. C. 1962. Methods of Tissue Culture. 3rd edn.. Harper and Row; New York:
• 18 Proctor R. R, and Rapaport S. I. 1961; The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. American Journal of Clinical Pathology 36: 212.
• 19 Scatchard G. 1949; The attractions of proteins for small molecules and ions. Annals of the New York Academy of Sciences 51: 660.
• 20 Schmer G, Kirby E. P, Teller D. C, and Davie E. W. 1972; The isolation and characterization of bovine Factor VIII (antihemophilic factor). Journal of Biological Chemistry 247: 2512.
• 21 Solum N. O. 1968; Aggregation of human platelets by bovine platelet fibrinogen. Scandinavian Journal of Haematology 5: 474.
• 22 Weiss H. J, Hoyer L. W, Bickles F. B, Varma A, and Bogers J. 1973; Quantitative assay of a plasma factor deficient in von Willebrand’s disease. Relationship to Factor VIII procoagulant activity and antigen content. Journal of Clinical Investigation 52: 2708.